Scientist takes on executive post.
A CARDIFF-BASED biotechnology company at the forefront of new drug delivery and DNA testing technology has appointed a top scientist as executive chairman.
Joining Q Chip with a career spanning more than three decades as a senior researcher and manager in the pharmaceutical sector, Professor Ken Powell is regarded by the industry as one of its pioneers.
Prof Powell's previous positions include being chief executive of Arrow Therapeutics, head of antiviral antiviral /an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts.
adj. research and head of biology at the Wellcome Foundation, and professor of virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression and cell biology at the Wolfson Institute for Biomedical Research at University College, London.
During his time at the Wolfson Institute, Prof Powell helped establish Inpharmatica, now part of Galapagos NV and Ark Therapeutics which listedon the London Stock Exchange London Stock Exchange
London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. in March 2004.
Prof Powell currently serves as head of Arrow Therapeutics which he founded in 1998 and which was acquired by Astrazeneca for EUR EUR
In currencies, this is the abbreviation for the Euro.
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 150m in February last year.
He said, "I have accepted the role of executive chairman of Q Chip for the simple reason I am excited by its prospects.
"It has undertaken some very exciting research which provides the foundations for a strong pipeline of applications and products."
Prof Powell is associated with some of the UK's most dynamic biotech companies.
Mark Barry, chief executive officer of Q Chip, said, "The fact he has chosen to take on an executive chairmanship role and his ability to attract investment for a series of commercially successful pharmaceutical research-based entities provides an enormous endorsement of the strategy Q Chip has been pursuing."
Last summer Q Chip completed a funding round which saw it raise inexcess of pounds 2mfromexisting and new shareholders to accelerate product development and commercialisation.